Helius Medical (HSDT) Technologies announced the establishment of Revelation Neuro, its wholly-owned private subsidiary focused on the development of non-implantable AI powered BCI technology. “We are thrilled to establish Revelation Neuro to pursue the development of a new gold standard of care for personalized neurorehabilitation using a non-implantable AI powered BCI combining our newly developed intellectual property with Helius’ existing IP. Our technology relies on its proven ability to modulate known target brain processes and trigger therapeutic responses by using translingual stimulation without risky implantation. We believe Revelation Neuro’s BCI technology will be a unique and less invasive therapeutic option,” said Dane Andreeff, Helius President and Chief Executive Officer.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HSDT:
- Helius Medical announces first reimbursement for PoNS Device
- Helius Medical files to sell 6.21M shares of common stock for holders
- Helius Medical Secures Funds Through Warrant Agreements
- Helius Medical announces statistically significant find in DGI in PoNSTEP study
- Helius Medical completes, exceeded target enrollment for stroke study
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue